MorphoSys Initiates Phase 2 Combination Trial of MOR208 and Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
April 06, 2016 01:37 ET
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, April 6, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the first patient was dosed in a phase 2...
Ad hoc: MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement
April 04, 2016 11:48 ET
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, April 4, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced that it filed a lawsuit in the United States (U.S.)...
MorphoSys AG Reports Results for Fiscal Year 2015
March 02, 2016 01:04 ET
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, March 2, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced financial results for the year ending December 31,...
Invitation to Year End 2015 Conference Call of MorphoSys AG on March 2, 2016
February 25, 2016 04:08 ET
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Feb. 25, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its Annual Financial Results 2015 on March 2, 2016 at 7:00 a.m....
MorphoSys Announces Share Buy-Back Program
February 24, 2016 11:02 ET
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Feb. 24, 2016 (GLOBE NEWSWIRE) -- The Management Board of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced with the approval of the...
MorphoSys Announces Clinical Milestone for Start of Bayer's Phase 2 Trial Designed to Support Registration of Anetumab Ravtansine
January 26, 2016 01:35 ET
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Jan. 26, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced that the company earned a milestone payment with...
MorphoSys to Present at J.P. Morgan Healthcare Conference
January 07, 2016 10:45 ET
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Jan. 7, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the upcoming J.P. Morgan Healthcare Conference in...
MorphoSys Presents Interim Safety, Pharmacokinetic and Efficacy Data for MOR202 in Multiple Myeloma at ASH Meeting
December 07, 2015 01:36 ET
|
MorphoSys AG
MOR202 produced encouraging response rates as single agent and in first combination cohorts with immunomodulatory drugs (IMiDs).
MOR202 is well tolerated and can be safely administered as a...
New Clinical Data on MorphoSys's Blood Cancer Drug Candidate MOR208 in NHL and CLL Presented at ASH Annual Meeting
December 07, 2015 01:34 ET
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Dec. 7, 2015 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced clinical data on its proprietary drug candidate...
MorphoSys to Present at Two Upcoming Conferences
November 16, 2015 08:10 ET
|
MorphoSys AG
MARTINSRIED and MUNICH, Germany, Nov. 16, 2015 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences:
Jefferies Autumn...